Published in Blood Weekly, February 10th, 2005
According to a study from the United States, "We assessed the pharmacokinetics of three different doses of indinavir in five patients."
"All doses achieved trough concentrations above efficacy thresholds. Toxic trough concentrations were observed in all patients receiving 800 mg, in two patients receiving 600 mg, and in none receiving 400 mg," L.S. Lee and coauthors reported.
"Indinavir at 400 mg may be efficacious and less toxic in patients taking ritonavir and efavirenz," concluded investigators.
Lee and colleagues published...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.